Exclusive interviews with leading policymakers that convey the true policy message that impacts markets.
Reporting on key macro data at the time of release.
Real-time insight on key fixed income and fx markets.
- Emerging MarketsEmerging Markets
Real-time insight of emerging markets in CEMEA, Asia and LatAm region
- Political RiskPolitical Risk
Intelligence on key political and geopolitical events around the world.
- About Us
Sign up now for free access to this content.
Please enter your details below and select your areas of interest.
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has recommended that the AstraZeneca COVID-19 vaccine is not offered to people under the age of 30 due to extremely rare cases of blood clots that may be linked to the vaccine.
- Figures from MHRA chief: 79 reports of blood clots after first AstraZeneca dose (51 women / 28 men), 19 died, 3 were under 30. Equates to 4 in 1 million doses dispensed ie 'very rare'.
- With under 30's still not due to be receiving vaccines unless they have a pre-existing condition it remains to be seen the impact of this decision on the vaccine rollout. The UK has already wound down its first dose offers in the month of April to ensure sufficient AZ vaccine supply for people's second doses.
- The rollout of the Moderna vaccine started in Wales today, and with 17mn doses due this could provide some of the doses needed to fill the AZ gap for the under 30s.
- Prof Wei Shen Lim, chair of the JCVI stated that "We are not advising a stop to any vaccination in any age group. We are advising a preference to a particular age group"
Slide used to justify MHRA decision